Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et studie, der evaluerer sygdomskarakteristika og resultater hos deltagere med astma i rutinemæssig klinisk praksis (AIRITY)

4. november 2026 opdateret af: Sanofi

Et hybrid tværsnits- og prospektivt studie til at vurdere patientkarakteristika, sygdomsbyrde, sygdomskontrol, fænotyper, endotyper og udfald i en real-world setting hos patienter med astma

The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.

The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.

Studieoversigt

Undersøgelsestype

Observationel

Tilmelding (Anslået)

2500

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Trial Transparency email recommended-Toll free for US & Canada
  • Telefonnummer: 6 800-633-1610
  • E-mail: Contact-US@sanofi.com

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T3R 1W7
        • Rekruttering
        • Investigational Site Number: 124203
    • Ontario
      • Windsor, Ontario, Canada, N8X 2G1
        • Rekruttering
        • Investigational Site Number: 124201
    • Quebec
      • Trois-Rivières, Quebec, Canada, G8T7A1
        • Rekruttering
        • Investigational Site Number: 124204
    • Alabama
      • Bessemer, Alabama, Forenede Stater, 35022
        • Rekruttering
        • Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
    • Arizona
      • Chandler, Arizona, Forenede Stater, 85224
        • Trukket tilbage
        • Chandler Clinical Trials - Site Number: 840106
      • Mesa, Arizona, Forenede Stater, 85206
        • Aktiv, ikke rekrutterende
        • Del Sol Research Management, LLC - Mesa - Site Number: 840123
      • Scottsdale, Arizona, Forenede Stater, 85254
        • Rekruttering
        • Orso Health - Scottsdale - Site Number: 840133
      • Sun City, Arizona, Forenede Stater, 85351
        • Aktiv, ikke rekrutterende
        • Sun City Clinical Trials - Elite - Site Number: 840120
    • California
      • California City, California, Forenede Stater, 91107
        • Aktiv, ikke rekrutterende
        • FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
      • La Palma, California, Forenede Stater, 90623
        • Aktiv, ikke rekrutterende
        • Imax Clinical Trials - Site Number: 840109
      • Los Angeles, California, Forenede Stater, 90017
        • Aktiv, ikke rekrutterende
        • Downtown LA Research - Site Number: 840161
      • Newport Beach, California, Forenede Stater, 92663
        • Aktiv, ikke rekrutterende
        • Newport Native MD, Inc. - Site Number: 840101
      • Pasadena, California, Forenede Stater, 91101
        • Aktiv, ikke rekrutterende
        • Pasadena Clinical Trials - Site Number: 840116
      • Tarzana, California, Forenede Stater, 91356
        • Trukket tilbage
        • Valiance Clinical Research (JPJ Research) - Site Number: 840135
      • Walnut Creek, California, Forenede Stater, 94598
        • Aktiv, ikke rekrutterende
        • Clinical Research of California - Site Number: 840145
    • Florida
      • Altamonte Springs, Florida, Forenede Stater, 32701
        • Aktiv, ikke rekrutterende
        • Cornerstone Research Institute, LLC - Site Number: 840152
      • Boca Raton, Florida, Forenede Stater, 33431
        • Aktiv, ikke rekrutterende
        • 3SYNC Research - Boca Raton - Site Number: 840148
      • Brandon, Florida, Forenede Stater, 33511
        • Aktiv, ikke rekrutterende
        • Meris Clinical Research - Site Number: 840167
      • Greenacres City, Florida, Forenede Stater, 33467
        • Aktiv, ikke rekrutterende
        • Finlay Medical Research - Site Number: 840107
      • Miami, Florida, Forenede Stater, 33126
        • Aktiv, ikke rekrutterende
        • EMDA Clinical Research - Site Number: 840113
      • Miami, Florida, Forenede Stater, 33126
        • Aktiv, ikke rekrutterende
        • Finlay Medical Research - Miami - Site Number: 840110
      • Miami, Florida, Forenede Stater, 33130
        • Aktiv, ikke rekrutterende
        • Care Research Inc. - Site Number: 840103
      • Miami, Florida, Forenede Stater, 33142
        • Aktiv, ikke rekrutterende
        • L&A Morales Healthcare, Inc - Site Number: 840102
      • Miami, Florida, Forenede Stater, 33145
        • Aktiv, ikke rekrutterende
        • MedOne Clinical Research - Site Number: 840122
      • Miami, Florida, Forenede Stater, 33155
        • Aktiv, ikke rekrutterende
        • D&H National Research Centers INC - Site Number: 840128
      • Miami, Florida, Forenede Stater, 33173
        • Aktiv, ikke rekrutterende
        • Research Institute Of South Florida - Site Number: 840149
      • Miami, Florida, Forenede Stater, 33174
        • Aktiv, ikke rekrutterende
        • Valencia Medical & Research Center, Corp - Site Number: 840153
      • Miami, Florida, Forenede Stater, 33186
        • Aktiv, ikke rekrutterende
        • Correa Research Center, Inc. - Site Number: 840141
      • Miami Gardens, Florida, Forenede Stater, 33014
        • Aktiv, ikke rekrutterende
        • Pro Care Research Center - Site Number: 840143
      • Miami Lakes, Florida, Forenede Stater, 33014
        • Aktiv, ikke rekrutterende
        • 3SYNC Research - Miami Lakes - Site Number: 840146
      • Miami Lakes, Florida, Forenede Stater, 33014
        • Aktiv, ikke rekrutterende
        • Deluxe Health Center - Site Number: 840117
      • Miami Lakes, Florida, Forenede Stater, 33016
        • Aktiv, ikke rekrutterende
        • MedQuest Translation Sciences, LLC - Site Number: 840162
      • North Miami Beach, Florida, Forenede Stater, 33169
        • Aktiv, ikke rekrutterende
        • Biscayne Clinical Research - Site Number: 840157
      • Palm Springs, Florida, Forenede Stater, 33406
        • Aktiv, ikke rekrutterende
        • CTMD Research, Inc - Site Number: 840147
      • Plantation, Florida, Forenede Stater, 33317
        • Aktiv, ikke rekrutterende
        • Edward Jenner Research Group, LLC - Site Number: 840169
      • Port Saint Lucie, Florida, Forenede Stater, 34986
        • Aktiv, ikke rekrutterende
        • Mark J. Pamer D.O., LLC - Site Number: 840121
      • Tamarac, Florida, Forenede Stater, 33321
        • Aktiv, ikke rekrutterende
        • TBC Research Corp - Site Number: 840132
      • Tampa, Florida, Forenede Stater, 33613
        • Aktiv, ikke rekrutterende
        • Avita Clinical Research - Tampa - Site Number: 840125
      • West Palm Beach, Florida, Forenede Stater, 33409
        • Aktiv, ikke rekrutterende
        • Palm Beach Medical & Research Center, Inc. - Site Number: 840165
    • Georgia
      • Columbus, Georgia, Forenede Stater, 31904
        • Aktiv, ikke rekrutterende
        • The Allergy Center at Brookstone - Site Number: 840114
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60616
        • Aktiv, ikke rekrutterende
        • Next Innovation Clinical Research - Chicago - Site Number: 840159
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40509
        • Aktiv, ikke rekrutterende
        • Bluegrass Allergy Care - Lexington - Site Number:840112
    • Maryland
      • Columbia, Maryland, Forenede Stater, 21045
        • Rekruttering
        • Columbia Medical Practice - Site Number: 840172
      • Rockville, Maryland, Forenede Stater, 20854
        • Aktiv, ikke rekrutterende
        • Velocity Clinical Research - Rockville - Site Number: 840163
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan - Ann Arbor - Site Number: 840140
    • Montana
      • Missoula, Montana, Forenede Stater, 59808
        • Aktiv, ikke rekrutterende
        • Montana Medical Research - Site Number: 840137
    • Nebraska
      • Papillion, Nebraska, Forenede Stater, 68046
        • Aktiv, ikke rekrutterende
        • Primary Clinical Research, LLC - Papillion - Site Number: 840168
    • New Jersey
      • Sewell, New Jersey, Forenede Stater, 08080
        • Aktiv, ikke rekrutterende
        • MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
    • New York
      • Cortland, New York, Forenede Stater, 13045
        • Aktiv, ikke rekrutterende
        • Finger Lakes Medical Research, PLLC - Site Number: 840155
      • New Windsor, New York, Forenede Stater, 12553
        • Aktiv, ikke rekrutterende
        • Mid Hudson Medical Research, PLLC - Site Number: 840139
      • New York, New York, Forenede Stater, 10029
        • Aktiv, ikke rekrutterende
        • Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
    • North Carolina
      • Asheville, North Carolina, Forenede Stater, 28801
        • Aktiv, ikke rekrutterende
        • Allergy Partners of Western North Carolina - Site Number: 840131
      • Gastonia, North Carolina, Forenede Stater, 28054-7489
        • Aktiv, ikke rekrutterende
        • Clinical Research of Gastonia (CRG) - Site Number: 840160
      • Greenville, North Carolina, Forenede Stater, 27834-2849
        • Rekruttering
        • East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
    • Ohio
      • Lima, Ohio, Forenede Stater, 45801
        • Aktiv, ikke rekrutterende
        • NexGen Research - Site Number: 840154
      • Toledo, Ohio, Forenede Stater, 43617
        • Aktiv, ikke rekrutterende
        • Toledo Institute of Clinical Research Inc - Site Number: 840105
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15241
        • Aktiv, ikke rekrutterende
        • Allergy and Clinical Immunology Associates - Site Number: 840127
    • South Carolina
      • Rock Hill, South Carolina, Forenede Stater, 29732
        • Aktiv, ikke rekrutterende
        • Clinical Research of Rock Hill - Site Number: 840115
    • Tennessee
      • Tennessee City, Tennessee, Forenede Stater, 30909
        • Aktiv, ikke rekrutterende
        • Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • Aktiv, ikke rekrutterende
        • Southwest Family Medicine Associates - Site Number: 840126
      • El Paso, Texas, Forenede Stater, 79902
        • Aktiv, ikke rekrutterende
        • El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
      • Houston, Texas, Forenede Stater, 77090
        • Aktiv, ikke rekrutterende
        • Lumi Research - Site Number: 840156
      • Houston, Texas, Forenede Stater, 77099
        • Aktiv, ikke rekrutterende
        • Pioneer Research Solutions - Site Number: 840104
      • Hurst, Texas, Forenede Stater, 76054
        • Aktiv, ikke rekrutterende
        • Lumi Research - Hurst - Site Number: 840164
      • Tomball, Texas, Forenede Stater, 77081
        • Aktiv, ikke rekrutterende
        • DM Clinical - Tomball - Site Number: 840130
    • Washington
      • Bellingham, Washington, Forenede Stater, 98225
        • Aktiv, ikke rekrutterende
        • Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
    • Brittany Region
      • Brest, Brittany Region, Frankrig, 29200
        • Rekruttering
        • Investigational Site Number: 250603
    • Occitanie
      • Lunel, Occitanie, Frankrig, 34400
        • Rekruttering
        • Investigational Site Number: 250612
      • Toulouse, Occitanie, Frankrig, 31059
        • Rekruttering
        • Investigational Site Number: 250607
    • Pays de la Loire Region
      • La Roche-sur-Yon, Pays de la Loire Region, Frankrig, 85000
        • Rekruttering
        • Investigational Site Number: 250613
    • Île-de-France Region
      • Argenteuil, Île-de-France Region, Frankrig, 95100
        • Rekruttering
        • Investigational Site Number: 250616
      • Créteil, Île-de-France Region, Frankrig, 94010
        • Rekruttering
        • Investigational Site Number: 250609
      • Niigata, Japan
        • Rekruttering
        • Investigational Site Number: 392707
    • Fukuoka
      • Kitakyushu-Shi, Fukuoka, Japan, 802-0083
        • Rekruttering
        • Investigational Site Number: 392705
    • Kagawa-ken
      • Takamatsu, Kagawa-ken, Japan, 761-8073
        • Rekruttering
        • Investigational Site Number: 392702
    • Saga-ken
      • Saga, Saga-ken, Japan, 849-8501
        • Rekruttering
        • Investigational Site Number: 392711
    • Tokyo
      • Bunkyo-ku, Tokyo, Japan, 113-8431
        • Rekruttering
        • Investigational Site Number: 392710
      • tabashi City, Tokyo, Japan, 173-8610
        • Rekruttering
        • Investigational Site Number: 392709
      • Madrid, Spanien, 28034
        • Rekruttering
        • Investigational Site Number: 724408
    • Bayern (Bavaria)
      • München, Bayern (Bavaria), Tyskland, 85039
        • Rekruttering
        • Investigational Site Number: 276503
    • North Rhine-Westphalia
      • Bonn, North Rhine-Westphalia, Tyskland, 53119
        • Rekruttering
        • Investigational Site Number: 276505
    • Saxony
      • Hohenstein-Ernstthal, Saxony, Tyskland, 09337
        • Rekruttering
        • Investigational Site Number: 276501
    • Schleswig-Holstein
      • Schleswig, Schleswig-Holstein, Tyskland, 24837
        • Rekruttering
        • Investigational Site Number: 276502

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

6 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.

Beskrivelse

Inclusion Criteria:

Applicable for Part 1 participants:

  • Age 6 years and older, at the time of signing the informed consent
  • Physician diagnosis of asthma for at least 12 months
  • Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
  • Participant or legally authorized representative (where applicable) has consented to participate

Applicable for Part 2 participants:

  • Age 18 years and older, at the time of signing the informed consent.
  • Physician diagnosis of asthma for at least 12 months
  • Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
  • Participant or legally authorized representative (where applicable) has consented to participate
  • Participants must meet the criteria for at least one of the cohorts below:

A) Asthma control cohorts

  1. ACQ-5 >= 1.5
  2. ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
  3. Elevated T2 biomarkers (B1: Type-2-high cohort)
  4. Low T2 biomarkers (B2: Type-2-low cohort)

Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):

  • Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
  • Participants with moderate/severe cognitive impairment.
  • Participants with moderate/severe cardiac disease.
  • Participants on immunosuppressive medication for a chronic condition.
  • Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Part-1: Participants With Asthma

Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice.

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: A1- Uncontrolled Asthma Cohort

Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: A2- Controlled Asthma Cohort

Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: B1- Type-2 (T2) High Asthma Cohort

Participants receiving SoC with elevated T2 biomarkers

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Part-2: B2- Type-2 Low Asthma Cohort

Participants receiving SoC with low T2 biomarkers

Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration.

Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
Tidsramme: Part 1: At baseline

Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function.

Part 1: At baseline
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
Tidsramme: Part 1: At baseline

ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID)

Part 1: At baseline
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
Tidsramme: Part 1: At baseline

The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment).

Part 1: At baseline
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
Tidsramme: Part 1: At baseline

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 1: At baseline
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
Tidsramme: Part 2: At Weeks 52 and 104

Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID.

Part 2: At Weeks 52 and 104
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
Tidsramme: Part 2: At Weeks 52 and 104

Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported.

Part 2: At Weeks 52 and 104
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
Tidsramme: Part-2: At Weeks 52 and 104

Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration.

Part-2: At Weeks 52 and 104

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Del 1: Antal deltagere karakteriseret ved deres demografiske og kliniske karakteristika
Tidsramme: Del 1: Fra 12 måneder før studiestart
Del 1: Fra 12 måneder før studiestart
Del 1: Antal deltagere karakteriseret ved deres sygdomsbyrde, helbredstilstand, behandlingserfaringer
Tidsramme: Del 1: Fra 12 måneder før deltagelse i studiet
Del 1: Fra 12 måneder før deltagelse i studiet
Del 1: Antal deltagere karakteriseret ved medicinbrug
Tidsramme: Del 1: Fra 12 måneder før studiestart
Del 1: Fra 12 måneder før studiestart
Del 1: Antal deltagere karakteriseret ved deres livsstil og miljømæssige påvirkninger
Tidsramme: Del 1: Fra 12 måneder før studiestart
Del 1: Fra 12 måneder før studiestart
Del 1: Antal deltagere karakteriseret ved brug af inhaleret og systemisk kortikosteroid
Tidsramme: Del 1: Fra 12 måneder før studiedeltagelsen
Del 1: Fra 12 måneder før studiedeltagelsen
Del 1: Antal deltagere karakteriseret ved sundhedsressourceudnyttelse (HCRU)
Tidsramme: Del 1: Fra 12 måneder før studiestart
Del 1: Fra 12 måneder før studiestart
Del 2: Beskrivende karakterisering inklusive sociodemografi, sygdomskarakteristika og behandlingshistorie.
Tidsramme: Del 2: Ved baseline
Del 2: Ved baseline
Del 2: Årlige eksacerbationsrater i uge 52 og 104
Tidsramme: Del 2: Uge 52 og 104
Del 2: Uge 52 og 104
<string>Del 2: Antal deltagere analyseret for ændringer i indåndet og systemisk kortikosteroidbyrde</string>
Tidsramme: Del 2: Fra baseline op til uge 104
Del 2: Fra baseline op til uge 104
Del 2: Ændringer i biomarkørniveau
Tidsramme: Del 2: I uge 52 og 104
Del 2: I uge 52 og 104
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
Tidsramme: Part 1: From 12 months prior to study enrollment

The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician.

Part 1: From 12 months prior to study enrollment
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
Tidsramme: Part 1: From 12 months prior to study enrollment

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Part 1: From 12 months prior to study enrollment
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
Tidsramme: Part 1: From 12 months prior to study enrollment

The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity.

Part 1: From 12 months prior to study enrollment
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tidsramme: Part 2: From baseline to week 52 and week 104

FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value).

Part 2: From baseline to week 52 and week 104
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
Tidsramme: Part 2: From baseline to week 52 and week 104

Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma.

Part 2: From baseline to week 52 and week 104
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
Tidsramme: Part 2: From baseline to week 52 and week 104

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 2: From baseline to week 52 and week 104
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
Tidsramme: Part 2: At Weeks 52 and 104

The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity.

Part 2: At Weeks 52 and 104
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
Tidsramme: Part 2: At Weeks 52 and 104

Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity.

Part 2: At Weeks 52 and 104
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
Tidsramme: Part 2: From baseline to week 52 and week 104

Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits.

Part 2: From baseline to week 52 and week 104
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
Tidsramme: Part 2: At Weeks 52 and 104

PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability.

Part 2: At Weeks 52 and 104
Part 2: Changes in Participant Survey Response
Tidsramme: Part 2: From baseline to week 52 and week 104

Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records.

Part 2: From baseline to week 52 and week 104

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. april 2026

Primær færdiggørelse (Anslået)

4. april 2029

Studieafslutning (Anslået)

4. april 2029

Datoer for studieregistrering

Først indsendt

31. marts 2026

Først indsendt, der opfyldte QC-kriterier

21. april 2026

Først opslået (Faktiske)

29. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • PIR21191
  • 2025-524916-13-00 (Ctis)
  • U1111-1336-5183 (Registry Identifier: ICTRP)
  • 2025 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner